论文部分内容阅读
非何杰金氏淋巴瘤(MHL)的治疗近几年来有很大的进展,特别是其中弥漫性大细胞型淋巴瘤,目前已40％以上病例可以通过积极化疗治愈至于所用治疗方案多以CHOP或CHOP-BICO作为根治性化疗的基本方案。现将我科1988年1月～1992年12月用“CHOP”方案治疗NHL 30例的情况报告如下。 一 般 资 料 30例中,男14例,女16例。年龄18～65岁,21～50岁26例(占86.1％)。全组病例均经病理组织学检查证实。初治24例,复治6例。临床分期(根据Ann、Arbnr会议制定的标准):Ⅰ_A 1例Ⅰ_B 4例,Ⅱ_A 2例,Ⅱ_B 2例,Ⅲ_A 1例,Ⅲ_B 1例,Ⅳ_A 3例,Ⅳ_B 15例,腹型1例,Ⅳ期占60％,病理分型,按NCI工作分型,低恶性5例(包括结节混合细胞型4例,结节硬化型1例);中度恶性7例(包括中度分化型2
Non-Hodgkin’s lymphoma (MHL) treatment has made great progress in recent years, especially in which diffuse large cell lymphoma, more than 40% of cases can be cured by active chemotherapy as the treatment used more than CHOP Or CHOP-BICO as the basic regimen of radical chemotherapy. Now our department January 1988 ~ December 1992 with the “CHOP” program for the treatment of NHL 30 cases are as follows. General information in 30 cases, 14 males and 16 females. Aged 18 to 65 years old, 21 to 50 years old in 26 cases (86.1%). All cases were confirmed by histopathological examination. 24 cases of initial treatment, 6 cases of retreatment. Clinical stage (according to Ann, Arbnr meeting set standards): Ⅰ_A 1 cases Ⅰ_B 4 cases, Ⅱ_A 2 cases, Ⅱ_B 2 cases, Ⅲ_A 1 cases, Ⅲ_B 1 cases, Ⅳ_A 3 cases, Ⅳ_B 15 cases, abdominal 1 case, Ⅳ Accounting for 60%, pathological type, according to the NCI classification, low malignant in 5 cases (including nodular mixed cell type in 4 cases, nodular sclerosis in 1 case); moderately malignant in 7 cases (including moderately differentiated type 2